Antibodies: Timeline of key events

Mouseover the event title for a more detailed description of the event (if available). To search for particular terms in the description of the event enter the term in the box below 'Event' on the table and press 'enter'. Alternatively use the dropdown lists to filter by Person, Place or Science. Click here to clear the filter.

The drug was developed by Genetech/Roche2016-05-01T00:00:00+0000J. Sevigny et al, 'The antibody aducanumab reduces A-beta plaques in Alzheimer’s disease', 'Nature', 37 (2016), 50-56.2016-09-01T00:00:00+0000It was the first time tyhe FDA approved an immune checkpoint inhibitor for the treatment of lung cancer. The drug was developed by Merck & Co.2016-10-24T00:00:00+0000Evidence collected from randomised, doublice-blind, placebo controled study of 27,000 patients in 49 countries between Feb 2013 and June 2015. MS Sabatine, et al, 'Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease', NEJM, 2017, DOI: 10.1056/NEJMoa1615664.2017-03-17T00:00:00+0000Developed by EMD Serono, avelumab was the first FDA approved product to treat metastatic Merckel cell carcinoma. Approval was given on the basis of basis of a clinical trial of 88 patient, 33% of whom experienced a complete or partial shrinkage of their tumours. In patients who responded, 86% had a response that last 6 months, and 45% had a response that lasted more than 12 months. The drug is being developed through an alliance between Merck KGaA and Pfizer. 2017-03-23T00:00:00+0000L. Xu, et al, 'Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques', Science, 20 September 2017, Science, 20 Sep 2017, eaan8630, DOI: 0.1126/science.aan86302017-09-20T00:00:00+0000The drug, a form of immunotherapy, is a PDL1 checkpoint inhibitor.2017-09-20T00:00:00+0000Treatment was given to Leopold Fotso, a 33 year old man at King's College London using natalizumab, a drug licensed for multiple sclerosis. The trial is being led by Oliver Howe. 2017-11-03T00:00:00+0000
Date Event People Places Sciences
1 May 2016FDA approved atezolizumab (Tecentriq®), an immune checkpoint inhibitor targeted at PD1, for the treatment of urothelial carcinoma, the most common form of bladder cancer Genentech, RocheImmune checkpoint inhibitor, Immuotherapy, Oncology, Monoclonal antibodies
1 Sep 2016Monoclonal antibody drug for Alzheimer's Disease shown to be promising in phase II clinical trialsSevigny, Chiao, Bussiere, WeinrebBiogen, Neuimmune, Butler Hospital, University of ZurchMonoclonal antibodies, Neuroscience
24 Oct 2016FDA approved pembrolizumab (Keytruda®) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as determined by an FDA-approved test. MerckImmune checkpoint inhibitors, Cancer immunotherapy, Oncology, Monoclonal antibodies
17 Mar 2017Monoclonal antibody shown to effectively cut cholesterol levels, thereby preventing heart attacks and strokes SabatineMonoclonal antibodies, Cardiovascular
23 Mar 2017FDA granted accelerated approval to avelumab, a PD-L1 checkpoint inhibitor, to treat Merkel cell carcinoma, a rare form of skin cancer treatment, in patients 12 years and older with metastatic Merkel cell carcinoma, a rare form of skin disorderEMD Serono, Merck KGaA, PfizerImmune checkpoint inhibitors, Cancer immunotherapy, Oncology, Monoclonal antibodies
20 Sep 2017Combination of three monoclonal antibodies reported to protect monkeys from HIV Xu, Pegu, Rao, Doria-Rose, Beninga, McKee, Lord, Wei, Deng, Louder, Schmidt, Mankoff, Wu, Asokan, Beil, Lange, Leuschner, Kruip, Sendak, Kwon, Zhou, Chen, Bailer, Wang, Choe, Tartaglia, Barouch, O’Dell, Todd, Burton, Roederer, Connors, Koup, Kwong, YangSanhofi, National Institute of Allergy and Infectious Disease, Harvard University, Massachusetts Institute of Technology, Scripps Research Institute, Monoclonal antibodies, Infectious diseases
20 Sep 2017Nivolumab (Opdivo®) made available for NHS patients with advanced lung cancer Honko, FreemanMedarex, Bristol-Myers Squibb, Ono PharmaceuticalImmune checkpoint inhibitors, Immunotherapy, Monoclonal antibodies
3 Nov 2017First patient treated in first clinical trial using monoclonal antibody drug to treat schizophreniaHoweKing's College LondonMonoclonal antibodies

1 May 2016

FDA approved atezolizumab (Tecentriq®), an immune checkpoint inhibitor targeted at PD1, for the treatment of urothelial carcinoma, the most common form of bladder cancer

1 Sep 2016

Monoclonal antibody drug for Alzheimer's Disease shown to be promising in phase II clinical trials

24 Oct 2016

FDA approved pembrolizumab (Keytruda®) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as determined by an FDA-approved test.

17 Mar 2017

Monoclonal antibody shown to effectively cut cholesterol levels, thereby preventing heart attacks and strokes

23 Mar 2017

FDA granted accelerated approval to avelumab, a PD-L1 checkpoint inhibitor, to treat Merkel cell carcinoma, a rare form of skin cancer treatment, in patients 12 years and older with metastatic Merkel cell carcinoma, a rare form of skin disorder

20 Sep 2017

Combination of three monoclonal antibodies reported to protect monkeys from HIV

20 Sep 2017

Nivolumab (Opdivo®) made available for NHS patients with advanced lung cancer

3 Nov 2017

First patient treated in first clinical trial using monoclonal antibody drug to treat schizophrenia